Herbalife Ltd. (NYSE: HLF), a leading health and wellness company, community, and platform, has announced an agreement to acquire certain assets from Bioniq, a UK-based personalized supplements company focused on making health more accessible and actionable. This acquisition supports Herbalife’s vision of evolving into a technology-enabled, data-driven health and wellness platform.
“Health and wellness are increasingly becoming personalized and guided by data,” said Herbalife Chief Executive Officer Stephan Gratziani. “By combining Bioniq’s personalized supplement technology with Pro2col and leveraging our global distributor network, we are expanding our ability to deliver personalized wellness solutions on a global scale.”

Bioniq develops personalized supplement formulas using its patented product personalization engine, an individual’s health background, and a proprietary database of biomarkers. These formulations are designed to meet the needs of a wide range of individuals, from everyday wellness consumers to elite athletes, including Cristiano Ronaldo.
The acquisition of Bioniq complements Herbalife’s prior acquisitions of Pro2col and Link BioSciences, allowing the company to offer a broader range of personalized nutritional supplements in multiple delivery formats. Combined with Herbalife’s global manufacturing expertise, this will enable the company to expand personalized nutrition efficiently and at scale.
“I founded Bioniq in 2019 with the goal of helping people optimize their wellbeing through a science-driven approach to nutrition that integrates biomarker and lifestyle data,” said Vadim Fedotov, Founder and President of Bioniq. “Joining Herbalife, with its global distributor network and commitment to wellness at scale, is an exciting step forward for us.”

As a long-time global nutrition partner of Herbalife and a shareholder of Bioniq, Cristiano Ronaldo shares the vision of accelerating access to personalized nutritional supplements through Herbalife’s global distribution network. “Biometrics and personalized nutrition have been central to helping me perform at the highest level,” said Ronaldo. “Having used both Herbalife and Bioniq products, I know how tailored nutrition can optimize performance. I am thrilled that Bioniq’s personalized supplements will now reach more people worldwide through Herbalife.”
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. The USD55 million purchase price will be paid over five years, including an initial USD10 million payment at closing, with up to USD95 million in contingent payments tied to future performance.
As part of the deal, Herbalife also obtained a call option to acquire Bioniq LAB, a platform focused on small molecules and peptides, providing strategic flexibility for potential long-term opportunities in a capital-efficient manner. Bioniq’s personalized nutritional supplements are expected to be offered later this year through Herbalife independent distributors in select European and U.S. markets, with additional regions to follow.
For more information, visit www.herbalife.com.